Education
About Us
Working with TipRanks
Follow Us
OncoZenge AB (DE:8LY)
FRANKFURT:8LY
Total Valuation
OncoZenge AB has a market cap or net worth of €6.78M. The enterprise value is €35.28M.
Market Cap€6.78M
Enterprise Value€35.28M
Share Statistics
OncoZenge AB has 11,713,244 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding11,713,244
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
OncoZenge AB’s return on equity (ROE) is -0.87 and return on invested capital (ROIC) is -87.29%.
Return on Equity (ROE)-0.87
Return on Assets (ROA)-0.76
Return on Invested Capital (ROIC)-87.29%
Return on Capital Employed (ROCE)-0.87
Revenue Per Employee1.00K
Profits Per Employee-8.69M
Employee Count1
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of OncoZenge AB is -5.06. OncoZenge AB’s PEG ratio is >-0.01.
PE Ratio-5.06
PS Ratio0.00
PB Ratio1.90
Price to Fair Value4.41
Price to FCF-2.92
Price to Operating Cash Flow-2.92
PEG Ratio>-0.01
Income Statement
In the last 12 months, OncoZenge AB had revenue of 1.00K and earned -8.69M in profits. Earnings per share was -0.74.
Revenue1.00K
Gross Profit1.00K
Operating Income-8.69M
Pretax Income-8.69M
Net Income-8.69M
EBITDA-8.69M
Earnings Per Share (EPS)-0.74
Cash Flow
In the last 12 months, operating cash flow was -8.76M and capital expenditures 0.00, giving a free cash flow of -8.76M billion.
Operating Cash Flow-8.76M
Free Cash Flow-8.76M
Free Cash Flow per Share-0.75
Dividends & Yields
OncoZenge AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.07
52-Week Price Change96.55%
50-Day Moving Average0.45
200-Day Moving Average0.51
Relative Strength Index (RSI)61.54
Average Volume (3m)0.00
Important Dates
OncoZenge AB upcoming earnings date is May 20, 2025, TBA Not Confirmed.
Last Earnings DateFeb 20, 2025
Next Earnings DateMay 20, 2025
Ex-Dividend Date―
Financial Position
OncoZenge AB as a current ratio of 3.09, with Debt / Equity ratio of 0.00%
Current Ratio3.09
Quick Ratio3.09
Debt to Market Cap0.00
Net Debt to EBITDA0.44
Interest Coverage Ratio0.00
Taxes
In the past 12 months, OncoZenge AB has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
OncoZenge AB EV to EBITDA ratio is -4.61, with an EV/FCF ratio of -4.57.
EV to Sales40.06K
EV to EBITDA-4.61
EV to Free Cash Flow-4.57
EV to Operating Cash Flow-4.57
Balance Sheet
OncoZenge AB has €3.86M in cash and marketable securities with kr0.00 in debt, giving a net cash position of -€3.86M billion.
Cash & Marketable Securities€3.86M
Total Debtkr0.00
Net Cash-€3.86M
Net Cash Per Share-€0.33
Tangible Book Value Per Share€0.26
Margins
Gross margin is 0.00%, with operating margin of -868500.00%, and net profit margin of -868800.00%.
Gross Margin0.00%
Operating Margin-868500.00%
Pretax Margin-868800.00%
Net Profit Margin-868800.00%
EBITDA Margin-868500.00%
EBIT Margin-868500.00%
Analyst Forecast
The average price target for OncoZenge AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―